Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer

被引：7
作者：
Gallicchio, L
Tkaczuk, K
Lord, G
Danton, M
Lewis, LM
Lim, CK
Flaws, JA
机构：
[1] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[3] Univ London, MRC, Bioanalyt Sci Grp, London, England
来源：
CANCER LETTERS | 2004年 / 211卷 / 01期
关键词：
breast cancer; tamoxifen; metabolism;
D O I：
10.1016/j.canlet.2004.04.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tamoxifen (TAM) is commonly used as an adjuvant treatment for breast cancer. Although patients taking TAM are often taking medications for comorbidities, data regarding the interaction of TAM with other medications are limited. Thus, this study was carried out to determine whether medications co-prescribed with TAM significantly influence the plasma concentrations of TAM and its metabolites (N-desmethyltamoxifen; N-DMT and 4-hydroxytamoxifen; 4-OHT) in 98 women diagnosed with breast cancer. Participants taking diuretics had significantly higher plasma concentrations of TAM and N-DMT than participants not taking a diuretic. Arthritis/pain medication intake was negatively associated with plasma TAM concentrations. Chemotherapeutic agents, allergy drugs, anti-depressants, and diabetes medications did not significantly alter plasma TAM or metabolite concentrations. This suggests that diuretic or an arthritis/pain medication may affect TAM metabolism. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：57 / 67
页数：11
相关论文
共 26 条
[1]   Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA [J].
Boocock, DJ ;
Brown, K ;
Gibbs, AH ;
Sanchez, E ;
Turteltaub, KW ;
White, INH .
CARCINOGENESIS, 2002, 23 (11) :1897-1901
[2]   TAMOXIFEN - A REAPPRAISAL OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE [J].
BUCKLEY, MMT ;
GOA, KL .
DRUGS, 1989, 37 (04) :451-490
[3]   THE EFFECT OF SPIRONOLACTONE TREATMENT ON THE CYTOCHROME P450-MEDIATED METABOLISM OF THE PYRROLIZIDINE ALKALOID SENECIONINE BY HEPATIC MICROSOMES FROM RATS AND GUINEA-PIGS [J].
CHUNG, WG ;
BUHLER, DR .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1994, 127 (02) :314-319
[4]  
Clarke M, 1998, LANCET, V351, P1451
[5]   Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes [J].
Crewe, HK ;
Ellis, SW ;
Lennard, MS ;
Tucker, GT .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :171-178
[6]   TAMOXIFEN METABOLISM - PHARMACOKINETIC AND INVITRO STUDY [J].
ETIENNE, MC ;
MILANO, G ;
FISCHEL, JL ;
FRENAY, M ;
FRANCOIS, E ;
FORMENTO, JL ;
GIOANNI, J ;
NAMER, M .
BRITISH JOURNAL OF CANCER, 1989, 60 (01) :30-35
[7]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388
[8]   Intraocular penetration of tamoxifen [J].
Flaxel, CJ ;
Mulholland, B ;
Haynes, B ;
Gregor, ZJ .
OPHTHALMOLOGY, 2000, 107 (11) :2006-2009
[9]   Implications of cytochrome P450 interactions when prescribing medication for hypertension [J].
Flockhart, DA ;
Tanus-Santos, JE .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (04) :405-412
[10]   THE PHARMACOLOGY AND CLINICAL USES OF TAMOXIFEN [J].
FURR, BJA ;
JORDAN, VC .
PHARMACOLOGY & THERAPEUTICS, 1984, 25 (02) :127-205
123